Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : final evidence report

Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : final evidence report

Collection:
Health Policy and Services Research
Contributor(s):
Institute for Clinical and Economic Review, issuing body.
New England Comparative Effectiveness Public Advisory Council, issuing body.
Publication:
Boston, MA : Institute for Clinical and Economic Review, December 2 2016
Language(s):
English
Format:
Text
Subject(s):
Comparative Effectiveness Research
Immunologic Factors -- therapeutic use
Psoriasis -- drug therapy
Adalimumab -- therapeutic use
Benchmarking
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Interleukin-12 -- antagonists & inhibitors
Interleukin-17
Interleukin-23 -- antagonists & inhibitors
Phosphodiesterase 4 Inhibitors
Phototherapy
Psoriasis -- immunology
Psoriasis -- therapy
Randomized Controlled Trials as Topic
Severity of Illness Index
Tumor Necrosis Factor-alpha -- antagonists & inhibitors
Ustekinumab -- therapeutic use
Value-Based Purchasing
Humans
United States
Genre(s):
Technical Report
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file (viii, ES27, 270 pages))
Illustrations:
Illustrations
NLM Unique ID:
101704696 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/101704696